公开(公告)号：US20250049779A1

公开(公告)日：2025-02-13

申请号：US18722189

申请日：2022-12-20

Applicant: Bayer Aktiengesellschaft

Inventor： Dr. Martina DELBECK ,  Dr. Michael HAHN

IPC: A61K31/4545 ,  A61K31/137 ,  A61K45/06

Abstract: The present invention relates to a combination of a noradrenaline reuptake inhibitor and α2-Adrenoceptor subtype C (alpha-2C) antagonists, in particular substituted heterocyclic carboxamides of formula (I) for the treatment and/or prophylaxis of sleep-related breathing disorders, preferably obstructive and central sleep apneas and snoring.

公开(公告)号：US20250041552A1

公开(公告)日：2025-02-06

申请号：US18792963

申请日：2024-08-02

Applicant: Kimberly Babiash

Inventor： Kimberly Babiash

IPC: A61M19/00 ,  A61J1/20 ,  A61K9/00 ,  A61K31/137 ,  A61K31/4164 ,  A61K31/4168 ,  A61K31/445 ,  A61K31/4468 ,  A61K31/4535 ,  A61K31/485

Abstract: A combination of a container and an injectable medical formulation for use in spinal anesthesia as part of a medical procedure includes the injectable medical formulation including a pre-determined amount of a local anesthetic; a pre-determined amount of a short-acting opioid, the short-acting opioid being one of fentanyl or sufentanil; and a pre-determined amount of a long-acting opioid, the long-acting opioid being one of morphine and hydromorphone. The container is a single apparatus in which the injectable medical formulation is packaged and stored as a single dose prior to the medical procedure. The injectable medical formulation is packaged and stored within the container prior to a window of imminency of the medical procedure.

公开(公告)号：US20250017850A1

公开(公告)日：2025-01-16

申请号：US18771332

申请日：2024-07-12

Applicant: HONEYWELL INTERNATIONAL INC

Inventor： ERIK BOLDT ,  GREGORY LAURENCE SMITH

IPC: A61K9/00 ,  A61K31/137 ,  A61K47/06 ,  A61K47/10 ,  A61K47/12

Abstract: Disclosed are medicinal compositions, and devices, methods and systems which use same, comprising a propellant and at least one medicinally active compound, said propellant comprising at least 1234ze(E) and ethanol.

公开(公告)号：US12194141B2

公开(公告)日：2025-01-14

申请号：US17142744

申请日：2021-01-06

Applicant: Nevakar Injectables Inc.

Inventor： Kumaresh Soppimath ,  Tushar Hingorani ,  Anant Patel

IPC: A61K9/00 ,  A61K31/137 ,  A61K31/225 ,  A61K47/02 ,  A61K47/12 ,  A61M5/145 ,  A61M5/178 ,  A61M5/31 ,  A61M25/00 ,  A61M39/10

Abstract: Pre-filled syringes, pharmaceutical compositions, and kits and methods relating to same allow for emergency administration of one or more drugs from prefilled glass syringes to a patient via a needleless connector. In preferred embodiments, the prefilled glass syringe has a drug volume of at least 5 mL, has a Luer-lock, and has a syringe tip with an internal channel that has a diameter of about 1.7 mm. Such syringes advantageously allow storage of emergency drugs without leaching of plastic materials and degradation, and substantially improve the safety profile where the syringe is attached to an IV line via a needleless connector.

公开(公告)号：US12194037B2

公开(公告)日：2025-01-14

申请号：US18529978

申请日：2023-12-05

Applicant: MICRONEB TECH HOLDINGS, INC.

Inventor： Pradeep Albert ,  Christine Nichols ,  David J. Condron ,  Brian Artze ,  Fadi Saba ,  Jesse Klein ,  Vijay Vad ,  Stephen Naeger

IPC: A61K31/485 ,  A61K9/00 ,  A61K9/08 ,  A61K31/137 ,  A61K31/4164 ,  A61K31/475 ,  A61K47/02 ,  A61M11/00 ,  A61M15/00

Abstract: A pharmaceutical composition and method for treating opioid overdose, opioid dependency, and xylazine exposure is disclosed, utilizing an aqueous solution of sodium chloride. This solution contains active ingredients such as naloxone and yohimbine in specific concentrations, with naloxone targeting opioid overdose and yohimbine aimed at counteracting xylazine effects. In various embodiments, additional components like tolazoline and different buffers can be included. The disclosure introduces a unique delivery system that features a capsule with a vibrating mesh atomizer for efficient administration. Specifically, for yohimbine, a dual-reservoir capsule design facilitates controlled mixing with diluents or buffers. The administration of this pharmaceutical composition can be achieved through multiple methods, including intramuscular, intravenous, and atomized routes. The atomizing device incorporates a removable cap and a resilient air bladder, ensuring effective drug delivery. This system offers precision and adaptability in treating conditions related to opioid overdose, dependency, and xylazine exposure.

公开(公告)号：US12194036B2

公开(公告)日：2025-01-14

申请号：US18495149

申请日：2023-10-26

Applicant: ANTECIP BIOVENTURES II LLC

Inventor： Herriot Tabuteau

IPC: A61K9/24 ,  A61K9/20 ,  A61K31/137 ,  A61K31/485

Abstract: This disclosure relates to administration of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg of bupropion hydrochloride, or a molar equivalent amount of a free base form or another salt form of bupropion; and 2) about 40-50 mg, about 44-46 mg, or about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of a free base form or another salt form of dextromethorphan in certain patient populations, such as patients having moderate renal impairment, patients having mild or moderate hepatic impairment, patients receiving a concomitant strong CYP2D6 inhibitor, patients who are known CYP2D6 poor metabolizers, those in need of an NMDA antagonist that does not cause dissociation, and those at risk of QT prolongation.

公开(公告)号：US12194032B2

公开(公告)日：2025-01-14

申请号：US17658494

申请日：2022-04-08

Applicant: ChemoCentryx, Inc.

Inventor： Zhenhua Miao ,  Thomas Schall ,  Rajinder Singh

IPC: A61K31/444 ,  A61K31/137 ,  A61K31/28 ,  A61K31/403 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/426 ,  A61K31/44 ,  A61K31/4418 ,  A61K31/4422 ,  A61K31/519 ,  A61K31/7034 ,  A61K35/545 ,  A61K39/395 ,  A61P13/12

Abstract: A method of treating focal segmental glomerulosclerosis with a compound of Formula I is provided. FSGS may be primary (no known cause) or secondary. The secondary FSGS may be associated with infections or viruses such as HIV, diseases such as sickle cell disease or lupus, toxins or drugs such as anabolic steroids, heroin or pamidronate, nephron loss and hyperfiltration, such as with chronic pyelonephritis and reflux, morbid obesity, or diabetes mellitus.

公开(公告)号：US20250000792A1

公开(公告)日：2025-01-02

申请号：US18883447

申请日：2024-09-12

Applicant: Belhaven BioPharma Inc.

Inventor： Scott Lyman ,  Barry Bleske ,  Ted William Lanpher

IPC: A61K9/00 ,  A61K31/137 ,  A61K31/277 ,  A61K31/417 ,  A61K47/02 ,  A61K47/26 ,  A61K47/38

Abstract: Provided herein are dry powder formulations comprising epinephrine alone or in combination with at least one enabling agent suitable for nasal application. Also provided are unit dose forms and devices comprising such formulations and methods of using such formulations for the treatment of various conditions including anaphylaxis, anaphylactoid reaction, respiratory conditions, hemodynamic collapse, and for administration during cardiopulmonary arrest and other life-threatening conditions.

公开(公告)号：US20240423996A1

公开(公告)日：2024-12-26

申请号：US18824811

申请日：2024-09-04

Applicant: Essentialis, Inc.

Inventor： Neil M. COWEN

IPC: A61K31/549 ,  A61K9/00 ,  A61K9/20 ,  A61K9/50 ,  A61K31/137 ,  A61K31/155 ,  A61K31/551 ,  A61K38/27 ,  A61K45/06 ,  C07D285/18 ,  C07D285/22

Abstract: Provided are immediate or prolonged administration of certain potassium ATP (KATP) channel openers, optionally in combination with growth hormone, to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of KATP channel openers that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are methods of co-administering KATP channel openers with other drugs (e.g., in combination with growth hormone) to treat diseases of humans and animals (e.g., Prader-Willi Syndrome (PWS), Smith-Magenis syndrome (SMS), and the like.

公开(公告)号：US12171731B2

公开(公告)日：2024-12-24

申请号：US18200557

申请日：2023-05-22

Applicant: Duke University ,  National University of Singapore

Inventor： Dwight D. Koeberl ,  Paul M. Yen ,  Benjamin L. Farah

IPC: A61K31/155 ,  A61K31/05 ,  A61K31/12 ,  A61K31/137 ,  A61K31/167 ,  A61K31/192 ,  A61K31/198 ,  A61K31/216 ,  A61K31/277 ,  A61K31/352 ,  A61K31/355 ,  A61K31/385 ,  A61K31/436 ,  A61K31/519 ,  A61K31/522 ,  A61K31/5415 ,  A61K31/55 ,  A61K31/575 ,  A61K31/7016 ,  A61K33/00 ,  A61K38/46 ,  A61K38/47 ,  A61P3/00

Abstract: The present disclosure is directed to methods of treating a steatosis- associated disorder by administering a therapeutic agent selected from a lysosomal enzyme, an autophagy-inducing agent, or a combination thereof. Steatosis-associated disorders discussed herein include GSD Ia, GSD Ib, GSD Ic, NAFLD, and NASH. Other embodiments are directed to methods of reversing steatosis, modulating autophagy, inducing autophagy, and reversing glycogen storage.